Gastroenterology
Volume 138, Issue 4 , Pages 1338-1345.e7 , April 2010

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study

  • Andri Rauch

      Affiliations

    • University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    • Corresponding Author InformationAndri Rauch, University Clinic of Infectious Diseases, University Hospital Bern, Inselspital PKT2 B, CH-3010 Bern, Switzerland. fax: (41) 31 328 43 60
    • ,
  • Zoltán Kutalik

      Affiliations

    • Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
    • Swiss Institute of Bioinformatics, Lausanne, Switzerland
    • ,
  • Patrick Descombes

      Affiliations

    • Genomics Platform, National Center of Competence in Research “Frontiers in Genetics,” University of Geneva, Geneva, Switzerland
    • ,
  • Tao Cai

      Affiliations

    • Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    • Infectious Diseases Service, Department of Internal Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
    • ,
  • Julia Di Iulio

      Affiliations

    • Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    • ,
  • Tobias Mueller

      Affiliations

    • Medical Clinic for Hepatology and Gastroenterology, Medical University Charité Campus, Virchow–Klinikum Berlin, Berlin, Germany
    • ,
  • Murielle Bochud

      Affiliations

    • University Institute for Social and Preventive Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
    • ,
  • Manuel Battegay

      Affiliations

    • Infectious Diseases and Infection Control Clinic, Department of Medicine, University Hospital Basel, Basel, Switzerland
    • ,
  • Enos Bernasconi

      Affiliations

    • Infectious Diseases Service, Regional Hospital, Lugano, Switzerland
    • ,
  • Jan Borovicka

      Affiliations

    • Division of Gastroenterology, Canton Hospital St Gallen, St Gallen, Switzerland
    • ,
  • Sara Colombo

      Affiliations

    • Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    • ,
  • Andreas Cerny

      Affiliations

    • Liver Unit, Clinica Luganese Moncucco, Lugano, Switzerland
    • ,
  • Jean–François Dufour

      Affiliations

    • Institute of Clinical Pharmacology and Visceral Research, University of Bern, Bern and University Clinic of Visceral Surgery and Medicine, Inselspital, Bern, Switzerland
    • ,
  • Hansjakob Furrer

      Affiliations

    • University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    • ,
  • Huldrych F. Günthard

      Affiliations

    • Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    • ,
  • Markus Heim

      Affiliations

    • Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland
    • ,
  • Bernard Hirschel

      Affiliations

    • Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland
    • ,
  • Raffaele Malinverni

      Affiliations

    • Pourtalès Hospital, Neuchâtel, Switzerland
    • ,
  • Darius Moradpour

      Affiliations

    • Division of Gastroenterology and Hepatology, University Hospital Lausanne, Lausanne, Switzerland
    • ,
  • Beat Müllhaupt

      Affiliations

    • Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland
    • ,
  • Andrea Witteck

      Affiliations

    • Infectious Diseases and Infection Control Unit, Canton Hospital St Gallen, St Gallen, Switzerland
    • ,
  • Jacques S. Beckmann

      Affiliations

    • Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
    • Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    • ,
  • Thomas Berg

      Affiliations

    • Medical Clinic for Hepatology and Gastroenterology, Medical University Charité Campus, Virchow–Klinikum Berlin, Berlin, Germany
    • ,
  • Sven Bergmann

      Affiliations

    • Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
    • Swiss Institute of Bioinformatics, Lausanne, Switzerland
    • ,
  • Francesco Negro

      Affiliations

    • Division of Gastroenterology and Hepatology, University Hospitals, Geneva, Switzerland
    • Division of Clinical Pathology, University Hospitals, Geneva, Switzerland
    • ,
  • Amalio Telenti

      Affiliations

    • Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    • ,
  • Pierre–Yves Bochud

      Affiliations

    • Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    • Infectious Diseases Service, Department of Internal Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
    • Corresponding Author InformationReprint requests Address requests for reprints to: Pierre-Yves Bochud, Infectious Diseases Service, Department of Medicine, Institute of Microbiology, Rue du Bugnon 48, CH-1011 Lausanne CHUV, Switzerland. fax: (41) 21 314 40 60
    • ,
  • Swiss Hepatitis C And HIV Cohort Studies

Received 8 October 2009 ,Accepted 29 December 2009.

References 

  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567
  2. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–456
  3. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–1754
  4. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52
  5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  7. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459
  8. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672
  9. Asselah T, Bieche I, Paradis V, et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis. 2007;27:13–27
  10. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:S19–S24
  11. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis. 2008;12:713–726xi
  12. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun. 2004;5:237–245
  13. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin (Irish Hepatology Research Group). N Engl J Med. 1999;340:1228–1233
  14. Muller R. The natural history of hepatitis C: clinical experiences. J Hepatol. 1996;24:52–54
  15. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634–651
  16. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257–267
  17. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260–1269
  18. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–2271
  19. Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus (The HENCORE group. Hepatitis C European Network for Cooperative Research). Lancet. 1999;354:2119–2124
  20. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872–874
  21. Knapp S, Hennig BJ, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 2003;55:362–369
  22. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003;4:411–419
  23. Wietzke-Braun P, Maouzi AB, Manhardt LB, et al. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2006;18:991–997
  24. Yee LJ, Perez KA, Tang J, et al. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis. 2003;187:1264–1271
  25. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005;54:1157–1161
  26. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801
  27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401
  28. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–1104
  29. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–1109
  30. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study (Swiss HIV Cohort Study). Lancet. 1999;353:863–868
  31. Prasad L, Spicher VM, Zwahlen M, et al. Cohort profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007;36:731–737
  32. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21–S29
  33. Li Y, Abecasis GR. Mach 1.0: rapid haplotype reconstruction and missing genotype inference. Am J Human Genet. 2009;2290–2295
  34. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904–909
  35. Novembre J, Stephens M. Interpreting principal component analyses of spatial population genetic variation. Nat Genet. 2008;40:646–649
  36. Lao O, Lu TT, Nothnagel M, et al. Correlation between genetic and geographic structure in Europe. Curr Biol. 2008;18:1241–1248
  37. Degli-Esposti MA, Andreas A, Christiansen FT, et al. An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics. 1992;35:355–364
  38. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–68
  39. Li M, Liu X, Zhou Y, et al. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009;86:23–32
  40. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77
  41. Melchjorsen J, Siren J, Julkunen I, et al. Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J Gen Virol. 2006;87:1099–1108
  42. Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006;80:4501–4509
  43. Brand S, Beigel F, Olszak T, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005;289:G960–G968
  44. Hou W, Wang X, Ye L, et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009;83:3834–3842
  45. Hong SH, Cho O, Kim K, et al. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007;126:245–249
  46. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005;79:3851–3854
  47. Zhu H, Butera M, Nelson DR, et al. Novel type I interferon IL-28A suppresses hepatitis viral RNA replication. Virol J. 2005;2:80
  48. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–1898
  49. Dodds MG, Hausman DF, Miller DM. Viral kinetic modeling during treatment with interferon lambda-1a in genotype 1 chronic hepatitis C patients. In: European Association for the Study of the Liver (EASL), 44th Annual Meeting. Copenhagen, Denmark. 1–4, 2009;
  50. Lawitz E, Zaman A, Muir AJ. Interim results from a phase 1b dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-rIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin. Hepatology. 2008;48:A–170
  51. Shiffman M, Lawitz E, Zaman A. PEG-IFN-lambda: antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection. In: European Association for the Study of the Liver (EASL), 44th Annual Meeting. Copenhagen, Denmark. 1–4, 2009;
  52. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317:944–947
  53. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767–1777
  54. Firmann M, Mayor V, Vidal PM, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6

 View this article's video abstract at www.gastrojournal.org.

 Conflicts of interest The authors disclose no conflicts.

 Funding The Swiss Hepatitis C and HIV Cohort Studies are supported by the Swiss National Science Foundation (3347C0-108782/1, grant nos. 3347-069366, 3247-116862, and 3100AO-116323/1, and Swiss HIV Cohort Study grant 543), the Swiss Federal Office for Education and Sciences (03.0599), and the European Commission (LSHM-CT-2004-503359; VIRGIL Network of Excellence on Antiviral Drug Resistance). Genotyping in the Swiss Hepatitis C Cohort Study and statistical analyses were supported by the Leenaards Foundation and Debiopharm S.A. Genotyping in the Swiss HIV Cohort Study was supported by an unrestricted grant by Essex Chemie AG, the Novaris Research Foundation, and Infectigen, Switzerland. P.-Y.B. is supported by the Swiss National Science Foundation (32003B_127613/1), and the Leenaards Foundation.

PII: S0016-5085(10)00008-9

doi: 10.1053/j.gastro.2009.12.056

Gastroenterology
Volume 138, Issue 4 , Pages 1338-1345.e7 , April 2010

Article Tools

* Image Usage & Resolution